Shares of Amgen Inc. AMGN slipped 1.37% to $272.05 Thursday, on what proved to be an all-around positive trading session for ...

Some research has shown that dividend-paying stocks significantly outperformed their non-dividend-paying peers over the past ...

It’s been 19 months since Amgen completed its $27.8 billion acquisition of Horizon Therapeutics, and the California company ...

Amgen on Thursday said its first-quarter profit rose 24%, driven by product sales, and said that while it is premature to ...

Amgen on Thursday said its first-quarter profit rose 24%, handily exceeding Wall Street expectations, as product sales ...

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options ...

Amgen's diverse portfolio ensures stability, but risks like high debt and biosimilar competition loom. Check out my look at ...

The stable outlook reflects S&P Global Ratings’ expectation that Amgen’s revenue and EBITDA will remain stable despite patent ...

The U.K. drug regulator on Wednesday approved Amgen’s (NASDAQ:AMGN) intravenous medication teprotumumab (Tepezza) as the ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Shares of Merck Merck & Co. Inc. and Amgen Amgen Inc. have contributed to the blue-chip gauge's intraday decline, as the Dow Dow Jones Industrial Average was most recently trading 274 points lower (-0 ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for Amgen’s Tepezza ...